AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03398902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual sleep
Description: The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
Study NCT04531891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
Study NCT01662804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 Monoclonal Antibody Combined with Interleukin-2
Description: One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
Study NCT03507452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).
Study NCT02809651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
Study NCT02733536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard endotracheal tube
Description: 1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
Study NCT02809651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
Study NCT00757380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trypan Blue
Description: Membranepeeling with TB
Study NCT00757380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brillant Blue
Description: Membranepeeling and membrana limitans interna peeling with BB
Study NCT00781027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Comparison of longitudinal phacoemulsification and torsional phacoemulsification
Study NCT03997695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise group
Description: The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
Study NCT02856204 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03616509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: 12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
Study NCT03997695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise plus kinesio taping group
Description: The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
Study NCT03388450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Enteral 1000 mg omega 3 fatty acid.
Study NCT03388450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enteral nutrition without omega 3 fatty acid.
Study NCT03616509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 months on placebo, sodium chloride 0,9% injections
Study NCT03236701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg White replacement
Description: Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
Study NCT01106066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, S-1, radiotherapy
Description: Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
Study NCT04619043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Orthotic
Study NCT00508872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
Study NCT00508872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
Study NCT00508872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Study NCT00508872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Study NCT01438281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops. topical administration
Study NCT03507452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.
Study NCT03462628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI plus low-voltage substrate modification
Description: CPVI plus low-voltage substrate modification in the left atrium during SR
Study NCT03462628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI alone
Description: circumferential pulmonary vein isolation
Study NCT03122327 — intervention group
Intervention type: OTHER
Intervention: Questionaires
Description: Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
Study NCT03316573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
Study NCT01084096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increasing use of Antenatal Corticosteroids (ACS)
Description: Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants.
Study NCT01101321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (Totowa) (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
Study NCT01101321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reformulated OXY (Wilson) (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
Study NCT00643006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Supervised walks with poles twice a week at moderate-high intensity
Study NCT00643006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: low intensive exercise
Description: Supervised walks once a week at low-intensity.
Study NCT02766335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02766335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02358902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS - DC stimulator, Neurocom, Germany
Study NCT02358902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active intervention of aerobic exercise
Description: different types of aerobic exercise
Study NCT02358902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo tDCS
Description: only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
Study NCT02358902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placebo AE
Description: the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
Study NCT05015829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine Stress Echocardiography
Description: Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
Study NCT04964102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
Description: Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
Study NCT03280264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: oral administration
Study NCT02377999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato
Study NCT04187755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime Injection
Description: Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
Study NCT04187755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime Injection
Description: Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
Study NCT00561119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine , paclitaxel
Description: Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks
Study NCT02733536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: C-MAC introduced with a h size 3 blade.
Study NCT04569734 — intervention group
Intervention type: PROCEDURE
Intervention: WATCHMAN device implant procedure utilizing ICE probe
Description: The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
Study NCT04456088 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 150 ppm Nitric Oxide delivered through LungFit Delivery System
Description: Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
Study NCT04456088 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 80 ppm Nitric Oxide delivered through LungFit Delivery System
Description: Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
Study NCT03263676 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Icon resuable underwear
Description: Reusable incontinence underwear
Study NCT03263676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable pad
Description: Standard market disposable pad
Study NCT01001754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rIL-29
Description: Weekly SC injections in combination with ribavirin for up to 48 weeks
Study NCT01001754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly SC injections in combination with ribavirin for up to 48 weeks
Study NCT01001754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Daily oral administration (400-600 mg BID)
Study NCT01001754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Daily oral administration (400-600 mg BID)
Study NCT03593889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care and peer support programme
Description: For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year.
Study NCT03593889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
Study NCT02905604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dmPFC iTBS
Description: 2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
Study NCT02905604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: dmPFC Sham iTBS
Description: Sham iTBS
Study NCT02641652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
Study NCT02641652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
Study NCT01936350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
Study NCT01936350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
Study NCT02321761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Description: Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
Study NCT04054375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
Study NCT00185224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: 7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
Study NCT00185224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D00264A (Triquilar)
Description: 7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
Study NCT02623582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Description: Given IV
Study NCT01211860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide Choline Controlled-Release Tablet
Description: DCCR 290 mg once a day for 10 days
Study NCT02623582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04301271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: 12 weeks 40 mg Simvastatin add-on
Study NCT04301271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 12 weeks Placebo add-on
Study NCT03998488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery.
Study NCT02794519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Study NCT02794519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Study NCT02794519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
Study NCT02794519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
Study NCT03144375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical optimization and education
Description: Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
Study NCT03144375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sinus surgery
Study NCT04165603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein
Study NCT04165603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein
Study NCT02186678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-CT
Study NCT03494582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral Hysteropexy
Description: Abdominal approach for uterine suspension
Study NCT03494582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacrospinous Hysteropexy
Description: Transvaginal approach for uterine suspension
Study NCT01635881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emerge™ 1.20 mm PTCA Dilatation Catheter
Description: The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures.
Study NCT04385134 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00774800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog